Royalty Pharma (RPRX) Minority Interest (2019 - 2026)

Royalty Pharma has disclosed Minority Interest across 8 years of filings, most recently posting $3.0 billion for Q1 2026.

• Minority Interest for Q1 2026 came in at $3.0 billion, down 1.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 billion (down 1.67% YoY), and the FY2025 annual result was $3.2 billion, down 4.65% from the prior year.
• Minority Interest came in at $3.0 billion for Q1 2026 at Royalty Pharma, down from $3.2 billion in the prior quarter.
• In the past five years, Minority Interest ranged from a high of $4.4 billion in Q2 2022 to a low of $3.0 billion in Q1 2026.
• The 5-year median for Minority Interest is $3.4 billion (2024), against an average of $3.6 billion.
• Across the five-year window, Minority Interest retreated 19.38% in 2023 and retreated 1.67% in 2026, its largest moves.
• Royalty Pharma's Minority Interest stood at $3.9 billion in 2022, then dropped by 8.71% to $3.6 billion in 2023, then retreated by 4.55% to $3.4 billion in 2024, then slipped by 4.65% to $3.2 billion in 2025, then decreased by 5.86% to $3.0 billion in 2026.
• The last three Minority Interest figures came in at $3.0 billion (Q1 2026), $3.2 billion (Q4 2025), and $3.2 billion (Q3 2025), per Business Quant data.